Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to evaluate budesonide levels in the blood following inhalation of single doses of VR647 Inhalation Suspension in children with wheezing, reactive airway disease or mild asthma using a nebulizer, the VR647 Inhalation System. Secondary objectives include the evaluation of the safety and tolerability of VR647 Inhalation Suspension administered using the VR647 Inhalation System.


Clinical Trial Description

The study consists of four visits; a screening visit (Visit 1), two dosing days (Visits 2 and 3) and a follow-up visit (Visit 4). On each dosing day a single dose of treatment will be administered. Blood samples will be collected on eight occasions from pre-dose up to 8 hours post-dose at each dosing visit. Treatment allocation at Visits 2 and 3 is determined by a balanced incomplete block design.

The screening period (including Visit 1) is between 2 and 30 days duration; there is a washout period of 4 to 10 days between each dose (Visits 2 and 3) and the follow-up safety assessment (Visit 4) will occur 5 to 9 days after Visit 3. Subjects and their parent(s)/legal guardian(s) have the option of an overnight stay the day before dosing (Day -1, Visit 2 and Day 7, Visit 3). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03421730
Study type Interventional
Source Vectura Limited
Contact
Status Completed
Phase Phase 1
Start date December 18, 2017
Completion date March 27, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT02269761 - Chest Ultrasound of ER Patients With Cough or SOB N/A
Enrolling by invitation NCT00775697 - Montelukast in Children With Wheezing Phase 4
Completed NCT00749528 - Evaluation of Toxic Metals, Trace Elements and Total Antioxidant Activity in Children With Recurrent Wheezing N/A
Recruiting NCT00494624 - Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children Phase 4
Completed NCT01452945 - Bedside Lung Ultrasound in Young Children Presenting to the Emergency Department (ED) With Wheezing N/A
Withdrawn NCT00628303 - A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants Phase 3
Active, not recruiting NCT01028560 - Allergy Immunotherapy for the Reduction of Asthma Phase 1/Phase 2
Completed NCT00626808 - A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children Phase 4
Completed NCT00507676 - Lung Function and Structure in Healthy Infants and Infants With Recurrent Wheezing N/A
Recruiting NCT03600428 - Safety of LAIV4 in Children With Asthma Phase 4
Recruiting NCT03377192 - Impedance Pneumography in Assessment of Asthma Control in Preschool Children N/A
Completed NCT01142505 - Wheeze and Intermittent Treatment Phase 3
Completed NCT03099902 - Secondhand Smoking in Asthmatic Children N/A
Terminated NCT00962299 - Effectiveness of Inhaled Corticosteroids in Preschool Children With Acute Dyspnea and Wheeze Phase 4
Recruiting NCT03203603 - VCSIP Follow-up Study
Completed NCT01272635 - Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids. Phase 3
Completed NCT01072552 - Effect of Palivizumab on Later Recurrent Wheezing in Preterm Infants N/A
Completed NCT00512382 - The Nature of Reflux-respiratory Symptoms Association in Difficult to Treat Wheezing\Coughing Babies N/A
Recruiting NCT03505216 - Swiss Paediatric Airway Cohort
Completed NCT02163096 - A Study to Assess Benign Joint Hypermobility Syndrome in Children With a History of Wheezing or Asthma N/A